Use of Disease-Modifying Therapies by Women With MS
Women of reproductive age were more likely to be diagnosed with multiple sclerosis (MS). Although...
Read MoreMay 27, 2022
Women of reproductive age were more likely to be diagnosed with multiple sclerosis (MS). Although...
Read MoreMay 23, 2022
In women with multiple sclerosis (MS) and clinically isolated syndrome (CIS), continuing disease...
Read MoreMay 23, 2022
In patients in the earlier stages of MS, an accelerated rate of spinal cord atrophy can indicate...
Read MoreMay 20, 2022
“It has previously been thought that [multiple sclerosis (MS)] is less common among non-European...
Read MoreMay 20, 2022
“Identifying an accurate prognostic biomarker in individuals with multiple sclerosis (MS) is...
Read MoreMay 19, 2022
Elevated levels of neurofilament light chain (NfL) are a known biomarker for neurodegeneration in conditions such as stroke, dementia, Multiple sclerosis, and Amyotrophic lateral sclerosis. A new study reveals that NfL may also...
Read MoreMay 19, 2022
Patients with relapsing multiple sclerosis (RMS) achieved No Evidence of Disease Activity (NEDA)...
Read MoreApr 26, 2022
Preoperative PET scanning among patients with high-risk, clinical stage 1 endometrial cancer (EC)...
Read MoreApr 25, 2022
Immunotherapy is underutilized in patients with advanced endometrial cancer (EC), even though...
Read MoreApr 25, 2022
The COVID-19 pandemic had a major effect on access to gynecologic care for women of all races and...
Read MoreApr 25, 2022
Prior research has examined sentinel lymph node (SLN) mapping among patients with a range of BMI...
Read MoreMar 31, 2022
April 2, 7:00 PM – 10:00 PM Industry Therapeutic Update from EMD Serono, Inc.: Early DMT switch considerations in MS and discussing the capacity to mount an immune response April 3, 5:00 PM – 5:30 PM AAN Leadership...
Read MoreMar 31, 2022
Proof of Vaccination + Mask Requirement All in-person attendees, exhibitors, press personnel, guests, and staff must complete the COVID-19 vaccination process with an acceptable vaccine and booster, if eligible, a minimum of 7...
Read MoreMar 28, 2022
For patients with multiple sclerosis (MS), ozanimod provides continued control of disease activity...
Read MoreMar 23, 2022
In individuals with multiple sclerosis (MS), researchers sought to determine the role of cognitive dysfunction in motor disability and structural disease-related burden. About 81 healthy controls and 109 relapsing-remitting (RR)...
Read MoreMar 23, 2022
In the OPTIMUM trial, researchers sought to determine disability, cognition, motor function, and multiple sclerosis (MS) fatigue in relation to baseline and change in brain volume (BV). Over the course of 108 weeks, patients...
Read MoreMar 23, 2022
For a study, the researchers sought to look at early-stage relapsing-remitting multiple sclerosis (RRMS) patients’ long-term prognosis (LTP) communication preferences and factors. A non-interventional, multicenter trial...
Read MoreMar 23, 2022
For a study, the researchers sought to determine the safety and tolerability of a ketogenic diet (KD) in relapsing MS patients and the influence on patient-reported, laboratory, and clinical outcome measures. Investigators...
Read MoreMar 23, 2022
For a study, the researchers sought to compare the efficacy and tolerability of a 6-week cognitive-behavioral approaches (CBT) program with booster sessions for a year to conventional therapy on the severity and impact of...
Read MoreMar 23, 2022
No evidence of disease activity 3 and 4 (NEDA-3 and NEDA-4) in RMS patients treated with ozanimod were evaluated. Data were gathered from a randomized phase 3 trial (RADIANCE, NCT02047734) comparing oral ozanimod 0.92 mg/d to...
Read More